open access
Long-term responses to molecularly targeted treatment and immunotherapy – groups of patients, management
- Department of Soft Tissue/Bone Sarcoma and Melanoma, Maria Sklodowska-Curie Institute – Oncology Center, Warsaw, Poland
open access
Abstract
The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma resulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment are more likely to benefit from treatment.
Abstract
The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma resulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment are more likely to benefit from treatment.
Keywords
ipilimumab; pembrolizumab; nivolumab; dabrafenib; trametinib; long-term survival; melanoma
Title
Long-term responses to molecularly targeted treatment and immunotherapy – groups of patients, management
Journal
Nowotwory. Journal of Oncology
Issue
Article type
Review paper
Pages
117-124
Published online
2019-10-31
Page views
458
Article views/downloads
547
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2019;69(3-4):117-124.
Keywords
ipilimumab
pembrolizumab
nivolumab
dabrafenib
trametinib
long-term survival
melanoma
Authors
Paweł Rogala
Katarzyna Kozak